Trial · NCT04767373
Adverse event totals12
The totals the trial posted for each group.
1 to 12 of 12
Download this page as JSON| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | RSV Season 1: Clesrovimab 105 mg | 7 | 2,421 |
| Total, all-cause mortality | RSV Season 1: Placebo | 3 | 1,211 |
| Total, all-cause mortality | RSV Season 2: Clesrovimab 105 mg | 0 | 1,017 |
| Total, all-cause mortality | RSV Season 2: Placebo | 0 | 501 |
| Total, other adverse events | RSV Season 1: Clesrovimab 105 mg | 1,432 | 2,409 |
| Total, other adverse events | RSV Season 1: Placebo | 724 | 1,202 |
| Total, other adverse events | RSV Season 2: Clesrovimab 105 mg | 0 | 0 |
| Total, other adverse events | RSV Season 2: Placebo | 0 | 0 |
| Total, serious adverse events | RSV Season 1: Clesrovimab 105 mg | 282 | 2,409 |
| Total, serious adverse events | RSV Season 1: Placebo | 151 | 1,202 |
| Total, serious adverse events | RSV Season 2: Clesrovimab 105 mg | 32 | 1,017 |
| Total, serious adverse events | RSV Season 2: Placebo | 20 | 501 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04767373/event-totals